Bright Minds Biosciences Files 6-K with Meeting Notices
Ticker: DRUG · Form: 6-K · Filed: May 17, 2024 · CIK: 1827401
| Field | Detail |
|---|---|
| Company | Bright Minds Biosciences INC. (DRUG) |
| Form Type | 6-K |
| Filed Date | May 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: meeting-notice, shareholder-meeting, corporate-governance
Related Tickers: BMBS
TL;DR
BMBS filed 6-K with shareholder meeting notices for March 22, 2024.
AI Summary
Bright Minds Biosciences Inc. filed a Form 6-K on May 17, 2024, reporting information for the month of March 2024. The filing includes a Notice of Meeting and Record Date (Exhibit 99.1) and a Notice of Annual General Meeting of Shareholders to be held on March 22, 2024 (Exhibit 99.2). The company is incorporated in A1 and has a fiscal year end of September 30.
Why It Matters
This filing provides shareholders with official notice of upcoming meetings, allowing them to participate in corporate governance and stay informed about company decisions.
Risk Assessment
Risk Level: low — This filing is primarily administrative, providing notice of meetings and not containing significant financial or operational updates.
Key Players & Entities
- BRIGHT MINDS BIOSCIENCES INC. (company) — Registrant
- March 22, 2024 (date) — Date of Annual General Meeting
- May 17, 2024 (date) — Filing Date
- 19 Vestry Street, New York, NY 10013 (address) — Principal Executive Office
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K filing serves as a report of a foreign private issuer and includes exhibits such as a Notice of Meeting and Record Date and a Notice of Annual General Meeting of Shareholders.
When was the Annual General Meeting of Shareholders scheduled to be held?
The Notice of Annual General Meeting of Shareholders indicates it was to be held on March 22, 2024.
What are the key exhibits included in this filing?
The key exhibits are Exhibit 99.1 (Notice of Meeting and Record Date) and Exhibit 99.2 (Notice of Annual General Meeting of Shareholders).
What is the principal executive office address for Bright Minds Biosciences Inc.?
The principal executive office is located at 19 Vestry Street, New York, NY 10013.
What is the SIC code for Bright Minds Biosciences Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 265 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-05-16 19:19:02
Filing Documents
- form6k.htm (6-K) — 7KB
- exhibit99-1.htm (EX-99.1) — 8KB
- exhibit99-2.htm (EX-99.2) — 8KB
- exhibit99-3.htm (EX-99.3) — 223KB
- exhibit99-4.htm (EX-99.4) — 1KB
- exhibit99-5.htm (EX-99.5) — 1KB
- exhibit99-6.htm (EX-99.6) — 5KB
- exhibit99-1x1x1.jpg (GRAPHIC) — 2KB
- exhibit99-3x001.jpg (GRAPHIC) — 33KB
- exhibit99-4xu003.jpg (GRAPHIC) — 175KB
- exhibit99-4xu004.jpg (GRAPHIC) — 124KB
- exhibit99-5xu002.jpg (GRAPHIC) — 124KB
- exhibit99-6x001.jpg (GRAPHIC) — 3KB
- 0001062993-24-010535.txt ( ) — 890KB
From the Filing
Bright Minds Biosciences Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [X] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ] SUBMITTED HEREWITH Exhibits 99.1 Notice of Meeting and Record Date 99.2 Notice of Annual General Meeting of Shareholders to be held on March 22, 2024 99.3 Management Information Circular dated as at February 5, 2024 99.4 Proxy Card relating to Annual General Meeting of Shareholders to be held on March 22, 2024 99.5 Financial Statement Request Form 99.6 News release dated March 27, 2024 re: Bright Minds Biosciences Announces Results of AGM SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. /s/ Ryan Cheung __________________________ Ryan Cheung Chief Financial Officer Date: May 16, 2024